Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2026 17:00 ET | Source: Adagene Inc.

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4...
March 31, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte

Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Rezurock est maintenant approuvé dans l’UE pour les adultes et les enfants âgés de 12 ans...
March 31, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new...
March 30, 2026 08:30 ET | Source: Transcenta

Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform

PRINCETON, N.J. and SUZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in...
March 30, 2026 05:57 ET | Source: Research and Markets

Cutaneous Squamous Cell Carcinoma (cSCC) Market Rises to $8.33 Billion in 2026: Roche, Merck & Co., and Sanofi Leads the Industry

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Cutaneous Squamous Cell Carcinoma (cSCC) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The cutaneous squamous cell...
March 30, 2026 05:51 ET | Source: Research and Markets

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Pancreatic Adenocarcinoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The pancreatic adenocarcinoma...
March 30, 2026 05:13 ET | Source: Research and Markets

Cancer Cachexia Market Outlook Report 2026-2030: Personalized Treatments and Digital Tools Elevate Cancer Cachexia Care; Total Revenue to Grow by $600 Million

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Cancer Cachexia Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides critical insights, including market size...
March 30, 2026 05:05 ET | Source: Research and Markets

Non-Small Cell Lung Cancer (NSCLC) Global Market Trends and Regional Growth Insights 2026-2030: Rapid Adoption of Targeted Therapies and Immunotherapy Fuels Market Expansion, Reaching $70.8 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Non-Small Cell Lung Cancer (NSCLC) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The non-small cell lung cancer...
March 28, 2026 15:00 ET | Source: MoonLake Immunotherapeutics AG

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated...
March 28, 2026 11:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute

AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute Dans les études de phase 3 COAST 1, COAST 2 et SHORE,...